Loading company…
Triplebar Bio uses high-throughput screening and engineered microbes to develop products for food, agriculture and pharmaceuticals.
Founded in 2019, Triplebar Bio is based in Emeryville, US, and combines hardware, software, biochemistry and biology to screen potential solutions for healthcare and nutrition. Its platform studies mutations and develops microbes that can produce molecules for food, agriculture and pharmaceutical applications. The company was founded by Jeremy Agresti and is led by CEO Maria Cho. In October 2023, it raised USD 20 million in Series A funding led by Synthesis Capital, with participation from Essential Capital, Stray Dog Capital and iSelect Fund Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in